Home » Pharma News » SPARC licenses Xelpros to Sun Pharma for US market

SPARC licenses Xelpros to Sun Pharma for US market

SPARC licenses Xelpros to Sun Pharma for US market

Sun Pharma Advanced Research Company (SPARC) has licensed out Xelpros, a preservative-free eye drop, to a subsidiary of Sun Pharma for the US market.

In addition to up-front payment of USD 3 million, SPARCBSE 2.83 % will receive certain other milestone payments, both totaling to USD 16 million from Sun Pharma, Sun Pharma and SPARC said in a joint statement today.

“It is also eligible for certain defined royalties and additional milestone payments linked to the actual ..

Thanks for the comment

Social Media Auto Publish Powered By : XYZScripts.com
%d bloggers like this: